AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2026
Mar 4, 2026
32883_dirs_2026-03-04_651ae130-7746-46c9-92f0-d360eed04a03.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2026-03-02
Reporting Person: Rodriguez Susan (CCSO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Stock Options | $53.47 | A | 48728 | Acquired | 2036-03-02 | Common Stock (48728) | Direct |
Footnotes
F1: Options vest 6/48ths on September 2, 2026 and 1/48th per month thereafter.
More from Monopar Therapeutics
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 14
Report Publication Announcement
2026
May 14
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 1
Annual Report
2026
Mar 27
Board/Management Information
2026
Mar 2
Director's Dealing
2026
Jan 30